首页 > 最新文献

Swiss medical weekly最新文献

英文 中文
Transdisciplinary sarcoma care: a model for sustainable healthcare transformation. 跨学科肉瘤治疗:可持续医疗转型的典范。
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-04-04 DOI: 10.57187/s.3473
Bruno Fuchs, Beata Bode, Philip Heesen, Barbara Kopf, Christian Michelitsch, Manfred Odermatt, Pietro Giovanoli, Stefan Breitenstein, Paul Schneider, Guido Schüpfer, Stefan Boes, Gabriela Studer
No abstract available.
无摘要。
{"title":"Transdisciplinary sarcoma care: a model for sustainable healthcare transformation.","authors":"Bruno Fuchs, Beata Bode, Philip Heesen, Barbara Kopf, Christian Michelitsch, Manfred Odermatt, Pietro Giovanoli, Stefan Breitenstein, Paul Schneider, Guido Schüpfer, Stefan Boes, Gabriela Studer","doi":"10.57187/s.3473","DOIUrl":"https://doi.org/10.57187/s.3473","url":null,"abstract":"No abstract available.","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140741556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipoprotein(a) as a blood marker for large artery atherosclerosis stroke etiology: validation in a prospective cohort from a swiss stroke center. 脂蛋白(a)作为大动脉粥样硬化中风病因的血液标志物:在瑞士中风中心前瞻性队列中的验证。
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-04-02 DOI: 10.57187/s.3633
Salome Rudin, L. Kriemler, Tolga D. Dittrich, Annaelle Zietz, J. Schweizer, M. Arnold, Nils Peters, Filip Barinka, Simon Jung, Marcel Arnold, Urs Fischer, Katharina Rentsch, M. Christ-Crain, Mira Katan, G. D. De Marchis
BACKGROUNDLipoprotein (a) [Lp(a)] serum levels are highly genetically determined and promote atherogenesis. High Lp(a) levels are associated with increased cardiovascular morbidity. Serum Lp(a) levels have recently been associated with large artery atherosclerosis (LAA) stroke. We aimed to externally validate this association in an independent cohort.METHODSThis study stems from the prospective multicentre CoRisk study (CoPeptin for Risk Stratification in Acute Stroke patients [NCT00878813]), conducted at the University Hospital Bern, Switzerland, between 2009 and 2011, in which Lp(a) plasma levels were measured within the first 24 hours after stroke onset. We assessed the association of Lp(a) with LAA stroke using multivariable logistic regression and performed interaction analyses to identify potential effect modifiers.RESULTSOf 743 patients with ischaemic stroke, 105 (14%) had LAA stroke aetiology. Lp(a) levels were higher for LAA stroke than non-LAA stroke patients (23.0 nmol/l vs 16.3 nmol/l, p = 0.01). Multivariable regression revealed an independent association of log10and#xA0;Lp(a) with LAA stroke aetiology (aOR 1.47 [95% CI 1.03and#x2013;2.09], p = 0.03). The interaction analyses showed that Lp(a) was not associated with LAA stroke aetiology among patients with diabetes.CONCLUSIONSIn a well-characterised cohort of patients with ischaemic stroke, we validated the association of higher Lp(a) levels with LAA stroke aetiology, independent of traditional cardiovascular risk factors. These findings may inform randomised clinical trials investigating the effect of Lp(a) lowering agents on cardiovascular outcomes. The CoRisk (CoPeptin for Risk Stratification in Acute Patients) study is registered on ClinicalTrials.gov.REGISTRATION NUMBERNCT00878813.
背景脂蛋白(a)[Lp(a)]血清水平由遗传因素高度决定,并促进动脉粥样硬化的发生。高脂蛋白(a)水平与心血管发病率增加有关。最近,血清脂蛋白(a)水平与大动脉粥样硬化(LAA)中风有关。本研究源于瑞士伯尔尼大学医院于 2009 年至 2011 年期间开展的前瞻性多中心 CoRisk 研究(CoPeptin for Risk Stratification in Acute Stroke patients [NCT00878813]),该研究在中风发病后 24 小时内测量血浆脂蛋白(a)水平。我们使用多变量逻辑回归评估了脂蛋白(a)与 LAA 中风的关系,并进行了交互分析以确定潜在的效应调节因子。结果 在 743 例缺血性中风患者中,105 例(14%)具有 LAA 中风病因。LAA 中风患者的脂蛋白(a)水平高于非 LAA 中风患者(23.0 nmol/l vs 16.3 nmol/l,p = 0.01)。多变量回归显示 log10 和#xA0;Lp(a)与 LAA 中风病因有独立关联(aOR 1.47 [95% CI 1.03 和#x2013;2.09],p = 0.03)。结论 在缺血性卒中患者队列中,我们验证了 Lp(a) 水平较高与 LAA 卒中病因的相关性,与传统的心血管风险因素无关。这些发现可为研究降低脂蛋白(a)药物对心血管预后影响的随机临床试验提供参考。CoRisk(用于急性期患者风险分层的CoPeptin)研究已在ClinicalTrials.gov.REGISTRATION NUMBERNCT00878813上注册。
{"title":"Lipoprotein(a) as a blood marker for large artery atherosclerosis stroke etiology: validation in a prospective cohort from a swiss stroke center.","authors":"Salome Rudin, L. Kriemler, Tolga D. Dittrich, Annaelle Zietz, J. Schweizer, M. Arnold, Nils Peters, Filip Barinka, Simon Jung, Marcel Arnold, Urs Fischer, Katharina Rentsch, M. Christ-Crain, Mira Katan, G. D. De Marchis","doi":"10.57187/s.3633","DOIUrl":"https://doi.org/10.57187/s.3633","url":null,"abstract":"BACKGROUND\u0000Lipoprotein (a) [Lp(a)] serum levels are highly genetically determined and promote atherogenesis. High Lp(a) levels are associated with increased cardiovascular morbidity. Serum Lp(a) levels have recently been associated with large artery atherosclerosis (LAA) stroke. We aimed to externally validate this association in an independent cohort.\u0000\u0000\u0000METHODS\u0000This study stems from the prospective multicentre CoRisk study (CoPeptin for Risk Stratification in Acute Stroke patients [NCT00878813]), conducted at the University Hospital Bern, Switzerland, between 2009 and 2011, in which Lp(a) plasma levels were measured within the first 24 hours after stroke onset. We assessed the association of Lp(a) with LAA stroke using multivariable logistic regression and performed interaction analyses to identify potential effect modifiers.\u0000\u0000\u0000RESULTS\u0000Of 743 patients with ischaemic stroke, 105 (14%) had LAA stroke aetiology. Lp(a) levels were higher for LAA stroke than non-LAA stroke patients (23.0 nmol/l vs 16.3 nmol/l, p = 0.01). Multivariable regression revealed an independent association of log10and#xA0;Lp(a) with LAA stroke aetiology (aOR 1.47 [95% CI 1.03and#x2013;2.09], p = 0.03). The interaction analyses showed that Lp(a) was not associated with LAA stroke aetiology among patients with diabetes.\u0000\u0000\u0000CONCLUSIONS\u0000In a well-characterised cohort of patients with ischaemic stroke, we validated the association of higher Lp(a) levels with LAA stroke aetiology, independent of traditional cardiovascular risk factors. These findings may inform randomised clinical trials investigating the effect of Lp(a) lowering agents on cardiovascular outcomes. The CoRisk (CoPeptin for Risk Stratification in Acute Patients) study is registered on ClinicalTrials.gov.\u0000\u0000\u0000REGISTRATION NUMBER\u0000NCT00878813.","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140754245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic characteristics of clinical non-toxigenic Vibrio cholerae isolates in Switzerland: a cross-sectional study. 瑞士临床非致毒霍乱弧菌分离物的基因组特征:一项横断面研究。
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-04-01 DOI: 10.57187/s.3437
Natalie Meyer, Roger Stephan, N. Cernela, J. Horlbog, M. Biggel
STUDY AIMSAlthough non-toxigenic Vibrio cholerae lack the ctxAB genes encoding cholera toxin, they can cause diarrhoeal disease and outbreaks in humans. In Switzerland, V. cholerae is a notifiable pathogen and all clinical isolates are analysed at the National Reference Laboratory for Enteropathogenic Bacteria and Listeria. Up to 20 infections are reported annually. In this study, we investigated the population structure and genetic characteristics of non-toxigenic V. cholerae isolates collected over five years.METHODS V. cholerae isolates were serotyped and non-toxigenic isolates identified using a ctxA-specific PCR. Following Illumina whole-genome sequencing, genome assemblies were screened for virulence and antibiotic resistance genes. Phylogenetic analyses were performed in the context of 965 publicly available V. cholerae genomes.RESULTSOut of 33 V. cholerae infections reported between January 2017 and January 2022 in Switzerland, 31 were caused by ctxA-negative isolates. These non-toxigenic isolates originated from gastrointestinal (n = 29) or extraintestinal (n = 2) sites. They were phylogenetically diverse and belonged to 29 distinct sequence types. Two isolates were allocated to the lineage L3b, a ctxAB-negative but tcpA-positive clade previously associated with regional outbreaks. The remaining 29 isolates were placed in lineage L4, which is associated with environmental strains. Genes or mutations associated with reduced susceptibility to the first-line antibiotics fluoroquinolones and tetracyclines were identified in 11 and 3 isolates, respectively. One isolate was predicted to be multidrug resistant.CONCLUSIONS V. cholerae infections in Switzerland are rare and predominantly caused by lowly virulent ctxAB-negative and tcpA-negative strains. As V. cholerae is not endemic in Switzerland, cases are assumed to be acquired predominantly during travel. This assumption was supported by the phylogenetic diversity of the analysed isolates.
研究目的虽然非致毒霍乱弧菌缺乏编码霍乱毒素的 ctxAB 基因,但它们仍可导致人类腹泻疾病和疫情爆发。在瑞士,霍乱弧菌是一种应通报的病原体,所有临床分离物都要在国家肠道致病菌和李斯特菌参考实验室进行分析。每年报告的感染病例多达 20 例。在这项研究中,我们调查了五年来收集到的非致毒霍乱弧菌分离株的种群结构和遗传特征。方法 使用ctxA特异性PCR对霍乱弧菌分离株进行血清分型并鉴定非致毒分离株。在进行 Illumina 全基因组测序后,对基因组组装进行了毒力基因和抗生素耐药性基因筛选。结果在 2017 年 1 月至 2022 年 1 月期间瑞士报告的 33 例霍乱弧菌感染中,31 例由 ctxA 阴性分离株引起。这些非致毒分离株来自胃肠道(29 株)或肠道外(2 株)。它们在系统发育上具有多样性,属于 29 个不同的序列类型。两个分离物被归入 L3b 系,这是一个 ctxAB 阴性但 tcpA 阳性的支系,以前曾与区域性疫情爆发有关。其余 29 个分离株被归入 L4 系,该系与环境菌株有关。在 11 个和 3 个分离株中分别发现了对一线抗生素氟喹诺酮类和四环素类药物敏感性降低的相关基因或突变。结论 在瑞士,霍乱弧菌感染非常罕见,主要由毒性较低的 ctxAB 阴性和 tcpA 阴性菌株引起。由于霍乱弧菌在瑞士没有流行,因此推测病例主要是在旅行途中感染的。分析分离菌株的系统发育多样性支持了这一假设。
{"title":"Genomic characteristics of clinical non-toxigenic Vibrio cholerae isolates in Switzerland: a cross-sectional study.","authors":"Natalie Meyer, Roger Stephan, N. Cernela, J. Horlbog, M. Biggel","doi":"10.57187/s.3437","DOIUrl":"https://doi.org/10.57187/s.3437","url":null,"abstract":"STUDY AIMS\u0000Although non-toxigenic Vibrio cholerae lack the ctxAB genes encoding cholera toxin, they can cause diarrhoeal disease and outbreaks in humans. In Switzerland, V. cholerae is a notifiable pathogen and all clinical isolates are analysed at the National Reference Laboratory for Enteropathogenic Bacteria and Listeria. Up to 20 infections are reported annually. In this study, we investigated the population structure and genetic characteristics of non-toxigenic V. cholerae isolates collected over five years.\u0000\u0000\u0000METHODS\u0000 V. cholerae isolates were serotyped and non-toxigenic isolates identified using a ctxA-specific PCR. Following Illumina whole-genome sequencing, genome assemblies were screened for virulence and antibiotic resistance genes. Phylogenetic analyses were performed in the context of 965 publicly available V. cholerae genomes.\u0000\u0000\u0000RESULTS\u0000Out of 33 V. cholerae infections reported between January 2017 and January 2022 in Switzerland, 31 were caused by ctxA-negative isolates. These non-toxigenic isolates originated from gastrointestinal (n = 29) or extraintestinal (n = 2) sites. They were phylogenetically diverse and belonged to 29 distinct sequence types. Two isolates were allocated to the lineage L3b, a ctxAB-negative but tcpA-positive clade previously associated with regional outbreaks. The remaining 29 isolates were placed in lineage L4, which is associated with environmental strains. Genes or mutations associated with reduced susceptibility to the first-line antibiotics fluoroquinolones and tetracyclines were identified in 11 and 3 isolates, respectively. One isolate was predicted to be multidrug resistant.\u0000\u0000\u0000CONCLUSIONS\u0000 V. cholerae infections in Switzerland are rare and predominantly caused by lowly virulent ctxAB-negative and tcpA-negative strains. As V. cholerae is not endemic in Switzerland, cases are assumed to be acquired predominantly during travel. This assumption was supported by the phylogenetic diversity of the analysed isolates.","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140774447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An in-hospital intervention to reduce the proportion of misused inhalers at hospital discharge among patients with COPD: a non-randomised intervention study. 减少慢性阻塞性肺病患者出院时滥用吸入器比例的院内干预:一项非随机干预研究。
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-04-01 DOI: 10.57187/s.3394
G. Grandmaison, Thomas Grobéty, Philippe Dumont, Julien Vaucher, Daniel Hayoz, Philipp Suter
AIMS OF THE STUDYMisuse of inhalers during chronic obstructive pulmonary disease (COPD) treatment is common and may result from errors in inhalation technique or insufficient peak inspiratory flow (PIF). We aimed to evaluate the impact of an in-hospital intervention to reduce inhaler misuse at hospital discharge among patients with COPD.METHODSWe conducted a monocentric, non-randomised intervention study to compare the proportion of misused inhalers at hospital discharge by patients with COPD between a group with standard care and a group receiving an in-hospital intervention. The control group successively included all patients hospitalised between March and June 2022, and the intervention group included patients hospitalised between August and December 2022. The intervention consisted of (a) an evaluation of inhalation technique and PIF at admission, (b) the provision of a written guide to assist in the selection of an inhaler, and (c) therapeutic education. The primary outcome was the proportion of misused inhalers, defined as an inhaler used with a critical error and/or insufficient PIF, at hospital discharge. The primary outcome was assessed by observing inhalation technique and measuring PIF using the In-Check DIAL G16® .RESULTSThe study included 93 patients: 46 in the control group and 47 in the intervention group. Mean age was 70.5 years (SD 10.9 years), 56 patients (60.2%) were men, and 57 patients (62%) were hospitalised for a COPD exacerbation. Patients used an average of 1.9 inhalers at hospital discharge; 98 inhalers were assessed in the control group and 81 in the intervention group. The proportion of misused inhalers at discharge was 61.2% in the control group and 21.0% in the intervention group (absolute risk reduction 40.2% [95% CI 25.5-55.0]; p <0.01). In the intervention group, the proportion of inhalers used with at least one critical error was reduced by 38.6% (95% CI 24.3-52.3%) and that of inhalers used with insufficient PIF by 13.9% (95% CI 4.2-23.6%).CONCLUSIONSAn in-hospital intervention was associated with a reduction in the proportion of misused inhalers at hospital discharge. This intervention should be considered for hospitalised patients with COPD. The trial was registered with ClinicalTrials.gov (NCT05207631).
研究目的 在慢性阻塞性肺病(COPD)治疗过程中滥用吸入器很常见,可能是由于吸入技术错误或吸入峰值流量(PIF)不足造成的。我们旨在评估院内干预对减少慢性阻塞性肺病患者出院时滥用吸入器的影响。方法 我们进行了一项单中心、非随机干预研究,比较了接受标准护理组和接受院内干预组的慢性阻塞性肺病患者出院时滥用吸入器的比例。对照组先后包括2022年3月至6月期间住院的所有患者,干预组包括2022年8月至12月期间住院的患者。干预措施包括:(a) 入院时对吸入技术和 PIF 进行评估;(b) 提供书面指南以协助选择吸入器;(c) 治疗教育。主要结果是出院时滥用吸入器的比例,滥用吸入器的定义是在使用吸入器时出现严重错误和/或PIF不足。主要结果通过观察吸入技术和使用 In-Check DIAL G16® 测量 PIF 进行评估:对照组 46 人,干预组 47 人。平均年龄为 70.5 岁(标清 10.9 岁),56 名患者(60.2%)为男性,57 名患者(62%)因慢性阻塞性肺疾病恶化住院。患者出院时平均使用 1.9 个吸入器;对照组评估了 98 个吸入器,干预组评估了 81 个。对照组出院时滥用吸入器的比例为 61.2%,干预组为 21.0%(绝对风险降低 40.2% [95% CI 25.5-55.0];P <0.01)。在干预组中,至少出现一次严重错误的吸入器使用比例降低了 38.6% (95% CI 24.3-52.3%),PIF 不足的吸入器使用比例降低了 13.9% (95% CI 4.2-23.6%)。慢性阻塞性肺病住院患者应考虑采取这种干预措施。该试验已在ClinicalTrials.gov(NCT05207631)上注册。
{"title":"An in-hospital intervention to reduce the proportion of misused inhalers at hospital discharge among patients with COPD: a non-randomised intervention study.","authors":"G. Grandmaison, Thomas Grobéty, Philippe Dumont, Julien Vaucher, Daniel Hayoz, Philipp Suter","doi":"10.57187/s.3394","DOIUrl":"https://doi.org/10.57187/s.3394","url":null,"abstract":"AIMS OF THE STUDY\u0000Misuse of inhalers during chronic obstructive pulmonary disease (COPD) treatment is common and may result from errors in inhalation technique or insufficient peak inspiratory flow (PIF). We aimed to evaluate the impact of an in-hospital intervention to reduce inhaler misuse at hospital discharge among patients with COPD.\u0000\u0000\u0000METHODS\u0000We conducted a monocentric, non-randomised intervention study to compare the proportion of misused inhalers at hospital discharge by patients with COPD between a group with standard care and a group receiving an in-hospital intervention. The control group successively included all patients hospitalised between March and June 2022, and the intervention group included patients hospitalised between August and December 2022. The intervention consisted of (a) an evaluation of inhalation technique and PIF at admission, (b) the provision of a written guide to assist in the selection of an inhaler, and (c) therapeutic education. The primary outcome was the proportion of misused inhalers, defined as an inhaler used with a critical error and/or insufficient PIF, at hospital discharge. The primary outcome was assessed by observing inhalation technique and measuring PIF using the In-Check DIAL G16® .\u0000\u0000\u0000RESULTS\u0000The study included 93 patients: 46 in the control group and 47 in the intervention group. Mean age was 70.5 years (SD 10.9 years), 56 patients (60.2%) were men, and 57 patients (62%) were hospitalised for a COPD exacerbation. Patients used an average of 1.9 inhalers at hospital discharge; 98 inhalers were assessed in the control group and 81 in the intervention group. The proportion of misused inhalers at discharge was 61.2% in the control group and 21.0% in the intervention group (absolute risk reduction 40.2% [95% CI 25.5-55.0]; p <0.01). In the intervention group, the proportion of inhalers used with at least one critical error was reduced by 38.6% (95% CI 24.3-52.3%) and that of inhalers used with insufficient PIF by 13.9% (95% CI 4.2-23.6%).\u0000\u0000\u0000CONCLUSIONS\u0000An in-hospital intervention was associated with a reduction in the proportion of misused inhalers at hospital discharge. This intervention should be considered for hospitalised patients with COPD. The trial was registered with ClinicalTrials.gov (NCT05207631).","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140772657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and outcomes of emergency department patients requiring emergency general surgery: a 5-year retrospective cohort study. 急诊科需要进行急诊普外科手术的患者的发病率和预后:一项为期 5 年的回顾性队列研究。
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-04-01 DOI: 10.57187/s.3729
C. Fehlmann, M. Taljaard, Daniel I McIssac, L. Suppan, Elisabeth Andereggen, Arnaud Dupuis, Frédéric Rouyer, D. Eagles, Jeffrey J Perry
AIMSPatients undergoing emergency general surgery are at high risk of complications and death. Our objectives were to estimate the incidence of emergency general surgery in a Swiss University Hospital, to describe the characteristics and outcomes of patients undergoing such procedures, and to study the impact of age on clinical outcomes.METHODSThis was a retrospective cohort study of adult patients who visited the emergency department (ED) of Geneva University Hospitals between January 2015 and December 2019. Routinely collected data were extracted from electronic medical records. The primary outcome was the incidence of emergency general surgery among patients visiting the emergency department, defined as general surgery within three days of emergency department admission. We also assessed demographic characteristics, mortality, intensive care unit admission and patient disposition. Multivariable log-binomial regression was used to study the associations of age with intensive care unit (ICU) admission, one-year mortality and dependence at discharge. Age was modelled as a continuous variable using restricted cubic splines and we compared older patients (75th percentile) with younger patients (25th percentile).RESULTSBetween January 2015 and December 2019, a total of 310,914 emergency department visits met our inclusion criteria. Among them, 3592 patients underwent emergency general surgery within 3 days of emergency department admission, yielding an annual incidence of 116 events per 10,000 emergency department visits (95% CI: 112-119), with a higher incidence in females and young patients. Overall, 5.3% of patients were admitted to ICU, 7.8% were dependent on rehabilitation or assisted living at discharge and 4.8% were dead after one year. Older patients had a higher risk of ICU admission (adjusted risk ratio (aRR) 2.9 [1.5-5.4]), dependence at discharge (aRR 15.3 [5.5-42.4]) and one-year mortality (aRR 5.4 [2.2-13.4]).CONCLUSIONEmergency department visits resulting in emergency general surgery are frequent, but their incidence decreases with patient age. Mortality, ICU admission and dependence at discharge following emergency general surgery are more frequent in older patients. Taking into account the increased risk for older patients, a shared process is appropriate for making more informed decisions about their options for care.
目的接受急诊普外科手术的患者面临并发症和死亡的高风险。我们的目标是估算瑞士一所大学医院的急诊普外科发病率,描述接受此类手术的患者的特征和预后,并研究年龄对临床预后的影响。方法这是一项回顾性队列研究,研究对象是2015年1月至2019年12月期间在日内瓦大学医院急诊科(ED)就诊的成年患者。从电子病历中提取了常规收集的数据。主要结果是急诊科就诊患者中急诊普通外科手术的发生率,定义为急诊科入院三天内的普通外科手术。我们还评估了人口统计学特征、死亡率、重症监护室入院情况和患者处置情况。我们使用多变量对数二叉回归法研究了年龄与入住重症监护室(ICU)、一年死亡率和出院时依赖性的关系。使用限制性三次样条将年龄作为连续变量建模,并将年龄较大的患者(第75百分位数)与年龄较小的患者(第25百分位数)进行比较。结果2015年1月至2019年12月期间,共有310914例急诊就诊符合我们的纳入标准。其中,3592 名患者在急诊科入院 3 天内接受了急诊普通外科手术,年发病率为每万名急诊科就诊者中有 116 例(95% CI:112-119),女性和年轻患者的发病率较高。总体而言,5.3%的患者住进了重症监护室,7.8%的患者出院时需要依靠康复或辅助生活,4.8%的患者一年后死亡。老年患者入住重症监护室(调整风险比 (aRR) 2.9 [1.5-5.4])、出院时依赖他人生活(aRR 15.3 [5.5-42.4])和一年后死亡(aRR 5.4 [2.2-13.4])的风险较高。年龄较大的患者在接受急诊普外科手术后,死亡率、入住重症监护室和出院时的依赖性更高。考虑到老年患者的风险增加,应采取共同流程,以便就护理方案做出更明智的决定。
{"title":"Incidence and outcomes of emergency department patients requiring emergency general surgery: a 5-year retrospective cohort study.","authors":"C. Fehlmann, M. Taljaard, Daniel I McIssac, L. Suppan, Elisabeth Andereggen, Arnaud Dupuis, Frédéric Rouyer, D. Eagles, Jeffrey J Perry","doi":"10.57187/s.3729","DOIUrl":"https://doi.org/10.57187/s.3729","url":null,"abstract":"AIMS\u0000Patients undergoing emergency general surgery are at high risk of complications and death. Our objectives were to estimate the incidence of emergency general surgery in a Swiss University Hospital, to describe the characteristics and outcomes of patients undergoing such procedures, and to study the impact of age on clinical outcomes.\u0000\u0000\u0000METHODS\u0000This was a retrospective cohort study of adult patients who visited the emergency department (ED) of Geneva University Hospitals between January 2015 and December 2019. Routinely collected data were extracted from electronic medical records. The primary outcome was the incidence of emergency general surgery among patients visiting the emergency department, defined as general surgery within three days of emergency department admission. We also assessed demographic characteristics, mortality, intensive care unit admission and patient disposition. Multivariable log-binomial regression was used to study the associations of age with intensive care unit (ICU) admission, one-year mortality and dependence at discharge. Age was modelled as a continuous variable using restricted cubic splines and we compared older patients (75th percentile) with younger patients (25th percentile).\u0000\u0000\u0000RESULTS\u0000Between January 2015 and December 2019, a total of 310,914 emergency department visits met our inclusion criteria. Among them, 3592 patients underwent emergency general surgery within 3 days of emergency department admission, yielding an annual incidence of 116 events per 10,000 emergency department visits (95% CI: 112-119), with a higher incidence in females and young patients. Overall, 5.3% of patients were admitted to ICU, 7.8% were dependent on rehabilitation or assisted living at discharge and 4.8% were dead after one year. Older patients had a higher risk of ICU admission (adjusted risk ratio (aRR) 2.9 [1.5-5.4]), dependence at discharge (aRR 15.3 [5.5-42.4]) and one-year mortality (aRR 5.4 [2.2-13.4]).\u0000\u0000\u0000CONCLUSION\u0000Emergency department visits resulting in emergency general surgery are frequent, but their incidence decreases with patient age. Mortality, ICU admission and dependence at discharge following emergency general surgery are more frequent in older patients. Taking into account the increased risk for older patients, a shared process is appropriate for making more informed decisions about their options for care.","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140769487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Core stories of physicians on a Swiss internal medicine ward during the first COVID-19 wave: a qualitative exploration. 瑞士内科病房医生在 COVID-19 第一波期间的核心故事:定性探索。
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-03-29 DOI: 10.57187/s.3760
Vanessa Kraege, Amaelle Gavin, Julieta Norambuena, Friedrich Stiefel, Marie Méan, Céline Bourquin

Introduction: The first COVID-19 wave (2020), W1, will remain extraordinary due to its novelty and the uncertainty on how to handle the pandemic. To understand what physicians went through, we collected narratives of frontline physicians working in a Swiss university hospital during W1.

Methods: Physicians in the Division of Internal Medicine of Lausanne University Hospital (CHUV) were invited to send anonymous narratives to an online platform, between 28 April and 30 June 2020. The analysed material consisted of 13 written texts and one audio record. They were examined by means of a narrative analysis based on a holistic content approach, attempting to identify narrative highlights, referred to as foci, in the texts.

Results: Five main foci were identified: danger and threats, acquisition of knowledge and practices, adaptation to a changing context, commitment to the profession, and sense of belonging to the medical staff. In physicians' narratives, danger designated a variety of rather negative feelings and emotions, whereas threats were experienced as being dangerous for others, but also for oneself. The acquisition of knowledge and practices focus referred to the different types of acquisition that took place during W1. The narratives that focused on adaptation reflected how physicians coped with W1 and private or professional upheavals. COVID-19 W1 contributed to revealing a natural commitment (or not) of physicians towards the profession and patients, accompanied by the concern of offering the best possible care to all. Lastly, sense of belonging referred to the team and its reconfiguration during W1.

Conclusions: Our study deepens the understanding of how physicians experienced the pandemic both in their professional and personal settings. It offers insights into how they prepared and reacted to a pandemic. The foci reflect topics that are inherent to a physician's profession, whatever the context. During a pandemic, these foundational elements are particularly challenged. Strikingly, these topics are not studied in medical school, thus raising the general question of how students are prepared for the medical profession.

导言:COVID-19 的第一波(2020 年),即 W1,由于其新颖性和如何应对大流行的不确定性,仍将是非同寻常的。为了了解医生的经历,我们收集了 W1 期间在瑞士一所大学医院工作的一线医生的叙述:方法:我们邀请洛桑大学医院(CHUV)内科的医生在 2020 年 4 月 28 日至 6 月 30 日期间向在线平台发送匿名叙述。分析材料包括 13 篇书面文字和 1 份录音。我们采用基于整体内容法的叙事分析方法对这些文本进行了研究,试图找出文本中的叙事重点(称为焦点):结果:确定了五个主要焦点:危险和威胁、知识和实践的获得、适应不断变化的环境、对职业的承诺以及对医务人员的归属感。在医生的叙述中,"危险 "指的是各种相当负面的感觉和情绪,而 "威胁 "则指对他人和对自己的危险。获取知识和实践的重点指的是 W1 期间发生的不同类型的获取。以适应为重点的叙述反映了医生如何应对 W1 和私人或职业动荡。COVID-19 W1有助于揭示医生对职业和病人的自然承诺(或不承诺),以及为所有人提供尽可能好的护理的关切。最后,归属感指的是 W1 期间的团队及其重组:我们的研究加深了对医生在职业和个人环境中如何经历大流行病的理解。我们的研究加深了对医生在职业和个人环境中如何经历大流行病的了解,并为他们如何准备和应对大流行病提供了见解。无论在什么情况下,研究的重点都反映了医生职业所固有的主题。在大流行病期间,这些基本要素尤其面临挑战。令人震惊的是,医学院并没有学习这些内容,这就提出了一个普遍的问题,即学生们是如何为从事医疗职业做好准备的。
{"title":"Core stories of physicians on a Swiss internal medicine ward during the first COVID-19 wave: a qualitative exploration.","authors":"Vanessa Kraege, Amaelle Gavin, Julieta Norambuena, Friedrich Stiefel, Marie Méan, Céline Bourquin","doi":"10.57187/s.3760","DOIUrl":"https://doi.org/10.57187/s.3760","url":null,"abstract":"<p><strong>Introduction: </strong>The first COVID-19 wave (2020), W1, will remain extraordinary due to its novelty and the uncertainty on how to handle the pandemic. To understand what physicians went through, we collected narratives of frontline physicians working in a Swiss university hospital during W1.</p><p><strong>Methods: </strong>Physicians in the Division of Internal Medicine of Lausanne University Hospital (CHUV) were invited to send anonymous narratives to an online platform, between 28 April and 30 June 2020. The analysed material consisted of 13 written texts and one audio record. They were examined by means of a narrative analysis based on a holistic content approach, attempting to identify narrative highlights, referred to as foci, in the texts.</p><p><strong>Results: </strong>Five main foci were identified: danger and threats, acquisition of knowledge and practices, adaptation to a changing context, commitment to the profession, and sense of belonging to the medical staff. In physicians' narratives, danger designated a variety of rather negative feelings and emotions, whereas threats were experienced as being dangerous for others, but also for oneself. The acquisition of knowledge and practices focus referred to the different types of acquisition that took place during W1. The narratives that focused on adaptation reflected how physicians coped with W1 and private or professional upheavals. COVID-19 W1 contributed to revealing a natural commitment (or not) of physicians towards the profession and patients, accompanied by the concern of offering the best possible care to all. Lastly, sense of belonging referred to the team and its reconfiguration during W1.</p><p><strong>Conclusions: </strong>Our study deepens the understanding of how physicians experienced the pandemic both in their professional and personal settings. It offers insights into how they prepared and reacted to a pandemic. The foci reflect topics that are inherent to a physician's profession, whatever the context. During a pandemic, these foundational elements are particularly challenged. Strikingly, these topics are not studied in medical school, thus raising the general question of how students are prepared for the medical profession.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of shift work and other work-related factors on anti-SARS-CoV-2 spike-protein serum concentrations in healthcare workers after primary mRNA vaccination - a retrospective cohort study. 轮班工作和其他工作相关因素对医护人员接种初级 mRNA 疫苗后抗 SARS-CoV-2 棘蛋白血清浓度的影响--一项回顾性队列研究。
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-03-27 DOI: 10.57187/s.3708
Gianluca Mauro Menghini, Robert Thurnheer, Christian R Kahlert, Philipp Kohler, Fabian Grässli, Reto Stocker, Manuel Battegay, Danielle Vuichard-Gysin

Background: Knowing whether shift work negatively affects the immune system's response to COVID-19 vaccinations could be valuable for planning future vaccination campaigns for healthcare workers. We aimed to determine the impact of working late or night shifts on serum anti-SARS-CoV-2 spike protein immunoglobulin G (anti-S) antibody levels after primary SARS-CoV-2-mRNA vaccination.

Methods: To obtain detailed information on shift work, we sent a separate online questionnaire to 1475 eligible healthcare workers who participated in a prospective longitudinal study conducted in 15 healthcare institutions in Switzerland. We asked all vaccinated healthcare workers with available anti-S antibody levels after vaccination to complete a brief online survey on their working schedules within one week before and after primary mRNA vaccination. We used multivariate regression to evaluate the association between work shifts around primary vaccination and anti-S antibody levels. We adjusted for confounders already known to influence vaccine efficacy (e.g. age, sex, immunosuppression, and obesity) and for variables significant at the 0.05 alpha level in the univariate analyses.

Results: The survey response rate was 43% (n = 638). Ninety-eight responders were excluded due to unknown vaccination dates, different vaccines, or administration of the second dose shortly (within 14 days) after or before serologic follow-up. Of the 540 healthcare workers included in our analysis, 175 (32.4%) had worked at least one late or night shift within seven days before and/or after primary vaccination. In the univariate analyses, working late or night shifts was associated with a nonsignificant -15.1% decrease in serum anti-S antibody levels (p = 0.090). In the multivariate analysis, prior infection (197.2% increase; p <0.001) and immunisation with the mRNA-1273 vaccine (63.7% increase compared to the BNT162b2 vaccine; p <0.001) were the strongest independent factors associated with increased anti-S antibody levels. However, the impact of shift work remained statistically nonsignificant (-13.5%, p = 0.108).

Conclusion: Working late or night shifts shortly before or after mRNA vaccination against COVID-19 does not appear to significantly impact serum anti-S antibody levels. This result merits consideration since it supports flexible vaccination appointments for healthcare workers, including those working late or night shifts.

背景:了解轮班工作是否会对免疫系统对 COVID-19 疫苗接种的反应产生负面影响,对于规划未来的医护人员疫苗接种活动很有价值。我们的目的是确定晚班或夜班对接种 SARS-CoV-2-mRNA 疫苗后血清中抗 SARS-CoV-2 尖峰蛋白免疫球蛋白 G(抗 S)抗体水平的影响:为了获得有关轮班工作的详细信息,我们向 1475 名符合条件的医护人员发送了一份单独的在线问卷,这些医护人员参加了在瑞士 15 家医疗机构开展的一项前瞻性纵向研究。我们要求所有接种疫苗后有抗 S 抗体水平的医护人员完成一份简短的在线调查,了解他们在接种初级 mRNA 疫苗前后一周内的工作时间安排。我们使用多元回归法评估了初次接种疫苗前后的工作班次与抗 S 抗体水平之间的关系。我们对已知会影响疫苗疗效的混杂因素(如年龄、性别、免疫抑制和肥胖)以及在单变量分析中显著性达到 0.05 alpha 水平的变量进行了调整:调查回复率为 43%(n = 638)。由于接种日期不详、接种了不同的疫苗或在血清学随访后不久(14 天内)或之前接种了第二剂疫苗,98 名回复者被排除在外。在纳入分析的 540 名医护人员中,有 175 人(32.4%)在初次接种疫苗之前和/或之后的七天内至少上过一次晚班或夜班。在单变量分析中,上晚班或夜班与血清抗 S 抗体水平下降-15.1%无显著相关性(p = 0.090)。在多变量分析中,既往感染(增加 197.2%;p = 0.090)与血清抗 S 抗体水平的下降无关(p = 0.090):接种 COVID-19 mRNA 疫苗前后上晚班或夜班似乎不会对血清抗 S 抗体水平产生显著影响。这一结果值得考虑,因为它支持医护人员(包括上晚班或夜班的医护人员)灵活预约疫苗接种时间。
{"title":"Impact of shift work and other work-related factors on anti-SARS-CoV-2 spike-protein serum concentrations in healthcare workers after primary mRNA vaccination - a retrospective cohort study.","authors":"Gianluca Mauro Menghini, Robert Thurnheer, Christian R Kahlert, Philipp Kohler, Fabian Grässli, Reto Stocker, Manuel Battegay, Danielle Vuichard-Gysin","doi":"10.57187/s.3708","DOIUrl":"https://doi.org/10.57187/s.3708","url":null,"abstract":"<p><strong>Background: </strong>Knowing whether shift work negatively affects the immune system's response to COVID-19 vaccinations could be valuable for planning future vaccination campaigns for healthcare workers. We aimed to determine the impact of working late or night shifts on serum anti-SARS-CoV-2 spike protein immunoglobulin G (anti-S) antibody levels after primary SARS-CoV-2-mRNA vaccination.</p><p><strong>Methods: </strong>To obtain detailed information on shift work, we sent a separate online questionnaire to 1475 eligible healthcare workers who participated in a prospective longitudinal study conducted in 15 healthcare institutions in Switzerland. We asked all vaccinated healthcare workers with available anti-S antibody levels after vaccination to complete a brief online survey on their working schedules within one week before and after primary mRNA vaccination. We used multivariate regression to evaluate the association between work shifts around primary vaccination and anti-S antibody levels. We adjusted for confounders already known to influence vaccine efficacy (e.g. age, sex, immunosuppression, and obesity) and for variables significant at the 0.05 alpha level in the univariate analyses.</p><p><strong>Results: </strong>The survey response rate was 43% (n = 638). Ninety-eight responders were excluded due to unknown vaccination dates, different vaccines, or administration of the second dose shortly (within 14 days) after or before serologic follow-up. Of the 540 healthcare workers included in our analysis, 175 (32.4%) had worked at least one late or night shift within seven days before and/or after primary vaccination. In the univariate analyses, working late or night shifts was associated with a nonsignificant -15.1% decrease in serum anti-S antibody levels (p = 0.090). In the multivariate analysis, prior infection (197.2% increase; p <0.001) and immunisation with the mRNA-1273 vaccine (63.7% increase compared to the BNT162b2 vaccine; p <0.001) were the strongest independent factors associated with increased anti-S antibody levels. However, the impact of shift work remained statistically nonsignificant (-13.5%, p = 0.108).</p><p><strong>Conclusion: </strong>Working late or night shifts shortly before or after mRNA vaccination against COVID-19 does not appear to significantly impact serum anti-S antibody levels. This result merits consideration since it supports flexible vaccination appointments for healthcare workers, including those working late or night shifts.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact on diabetes control and patient-reported outcomes of a newer implantable continuous glucose monitoring system (Eversense® CGM System): a single-centre retro- and prospective observational study 较新的植入式连续血糖监测系统(Eversense® CGM 系统)对糖尿病控制和患者报告结果的影响:单中心回顾性和前瞻性观察研究
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-03-20 DOI: 10.57187/s.3366
Dimitri Guy Rohner, Lukas Burget, Christoph Henzen, Stefan Fischli, Dr. med. Stefan Fischli
AIMS OF THE STUDY: The Eversense® CGM System is the first and only continuous glucose monitoring system (CGMS) that uses a fully subcutaneous implanted sensor. This study aimed to evaluate effectiveness, safety and patient-reported outcomes in patients using the Eversense® CGM System in a realistic clinical setting, assessed at a single Swiss diabetes centre (Luzerner Kantonsspital) with prolonged follow-up.METHODS: This was a prospective and retrospective observational study that included patients with type 1 diabetes mellitus in whom at least one Eversense® glucose sensor was implanted between 2017 and 2022. The primary endpoint was the change in HbA1c levels from the baseline (before implantation of the sensor) to 6 ± 2 and 12 ± 2 months and the last follow-up (newest available value) after implantation. The secondary outcome measures were the number of premature sensor breakdowns, adverse events related to the implantation procedure (infection, bleeding, difficulties with implantation or explantation) and patient-related outcomes (assessed with a questionnaire).RESULTS: A total of 33 patients participated in this study. The median follow-up time was 50 (IQR 22.3–58.5) months. In total, 178 sensor implantations were performed. Valid HbA1c results were available for 26 participants. Compared to the baseline values, HbA1c levels at 6 and 12 months and the last follow-up changed by –0.25%, –0.45 and –0.2 (p = 0.278, 0.308 and 0.296, respectively). We recorded 16 (9%) premature sensor breakdowns, all occurring between 2019 and 2020. Apart from one late-onset infection and four complicated sensor removals, no major complications were assessed. The results of the questionnaire showed a subjective improvement in hypoglycaemia rates, a better perception of hypoglycaemia and the impression of better diabetes management. Common issues with the device reported by the patients were technical errors (connection problems) and problems with the removal procedure.CONCLUSIONS: The use of the Eversense® CGM System resulted in changes in HbA1c of between –0.2% and –0.45%. The rate of premature sensor breakdown was low. Major complications following sensor implantation or removal were absent, apart from one case of infection and four cases of complicated removal. Patient-reported outcomes with the Eversense® CGM System showed a subjective positive impact on hypoglycaemia rates, greater confidence in managing hypoglycaemia and diabetes in general, and easy handling of the transmitter and mobile app. Technical issues must be considered but are nowadays, with the use of the newest sensor generation, very rare.
研究目的:Eversense® CGM 系统是首款也是唯一一款使用完全皮下植入式传感器的连续血糖监测系统 (CGMS)。本研究旨在评估在真实临床环境中使用 Eversense® CGM 系统的有效性、安全性和患者报告的结果,在瑞士一家糖尿病中心(Luzerner Kantonsspital)进行评估,并进行长期随访。方法:这是一项前瞻性和回顾性观察研究,研究对象包括在 2017 年至 2022 年期间植入至少一个 Eversense® 血糖传感器的 1 型糖尿病患者。主要终点是植入传感器后,从基线(植入传感器前)到6±2个月和12±2个月以及最后一次随访(最新可用值)期间的HbA1c水平变化。次要结果指标为传感器过早损坏的次数、与植入过程相关的不良事件(感染、出血、植入或拆卸困难)以及与患者相关的结果(通过问卷进行评估)。中位随访时间为 50 个月(IQR 22.3-58.5)。总共植入了 178 个传感器。有 26 名参与者获得了有效的 HbA1c 结果。与基线值相比,6 个月、12 个月和最后一次随访时的 HbA1c 水平变化分别为-0.25%、-0.45 和-0.2(p = 0.278、0.308 和 0.296)。我们记录了 16 次(9%)传感器过早故障,均发生在 2019 年至 2020 年期间。除了一次晚期感染和四次复杂的传感器拆卸外,没有评估出重大并发症。问卷调查结果显示,低血糖发生率有了主观改善,对低血糖有了更好的认识,对糖尿病管理有了更好的印象。患者报告的设备常见问题是技术错误(连接问题)和拆卸程序问题:结论:使用 Eversense® CGM 系统后,HbA1c 的变化在 -0.2% 到 -0.45% 之间。传感器过早损坏的比率很低。除了一例感染和四例复杂的移除之外,传感器植入或移除后没有出现重大并发症。Eversense® CGM 系统的患者报告结果显示,该系统对低血糖发生率产生了主观上的积极影响,患者对控制低血糖和糖尿病有了更大的信心,而且发射器和移动应用程序易于操作。技术问题是必须考虑的,但随着最新一代传感器的使用,如今技术问题已非常罕见。
{"title":"Impact on diabetes control and patient-reported outcomes of a newer implantable continuous glucose monitoring system (Eversense® CGM System): a single-centre retro- and prospective observational study","authors":"Dimitri Guy Rohner, Lukas Burget, Christoph Henzen, Stefan Fischli, Dr. med. Stefan Fischli","doi":"10.57187/s.3366","DOIUrl":"https://doi.org/10.57187/s.3366","url":null,"abstract":"AIMS OF THE STUDY: The Eversense® CGM System is the first and only continuous glucose monitoring system (CGMS) that uses a fully subcutaneous implanted sensor. This study aimed to evaluate effectiveness, safety and patient-reported outcomes in patients using the Eversense® CGM System in a realistic clinical setting, assessed at a single Swiss diabetes centre (Luzerner Kantonsspital) with prolonged follow-up.\u0000METHODS: This was a prospective and retrospective observational study that included patients with type 1 diabetes mellitus in whom at least one Eversense® glucose sensor was implanted between 2017 and 2022. The primary endpoint was the change in HbA1c levels from the baseline (before implantation of the sensor) to 6 ± 2 and 12 ± 2 months and the last follow-up (newest available value) after implantation. The secondary outcome measures were the number of premature sensor breakdowns, adverse events related to the implantation procedure (infection, bleeding, difficulties with implantation or explantation) and patient-related outcomes (assessed with a questionnaire).\u0000RESULTS: A total of 33 patients participated in this study. The median follow-up time was 50 (IQR 22.3–58.5) months. In total, 178 sensor implantations were performed. Valid HbA1c results were available for 26 participants. Compared to the baseline values, HbA1c levels at 6 and 12 months and the last follow-up changed by –0.25%, –0.45 and –0.2 (p = 0.278, 0.308 and 0.296, respectively). We recorded 16 (9%) premature sensor breakdowns, all occurring between 2019 and 2020. Apart from one late-onset infection and four complicated sensor removals, no major complications were assessed. The results of the questionnaire showed a subjective improvement in hypoglycaemia rates, a better perception of hypoglycaemia and the impression of better diabetes management. Common issues with the device reported by the patients were technical errors (connection problems) and problems with the removal procedure.\u0000CONCLUSIONS: The use of the Eversense® CGM System resulted in changes in HbA1c of between –0.2% and –0.45%. The rate of premature sensor breakdown was low. Major complications following sensor implantation or removal were absent, apart from one case of infection and four cases of complicated removal. Patient-reported outcomes with the Eversense® CGM System showed a subjective positive impact on hypoglycaemia rates, greater confidence in managing hypoglycaemia and diabetes in general, and easy handling of the transmitter and mobile app. Technical issues must be considered but are nowadays, with the use of the newest sensor generation, very rare.","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140226810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A cohort study of patients hospitalised with SARS-CoV-2 infection in Ontario: patient characteristics and outcomes by wave 安大略省因感染 SARS-CoV-2 而住院的患者队列研究:按波次分列的患者特征和治疗效果
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-03-13 DOI: 10.57187/s.3636
S. Habbous, Anna Lambrinos, Kirsten Ming, Erik Hellsten
INTRODUCTION: Each wave of the COVID-19 pandemic exhibited a unique combination of epidemiological, social and structural characteristics. We explore similarities and differences in wave-over-wave characteristics of patients hospitalised with COVID-19.METHODS: This was a population-based study in Ontario province, Canada. Patients hospitalised with SARS-CoV-2 between 26 February 2020 and 31 March 2022 were included. An admission was considered related to SARS-CoV-2 infection if the provincial inpatient or outpatient hospital databases contained the ICD-10 diagnostic codes U071/U072 or the Ontario Laboratories Information System indicated a positive SARS-CoV-2 test result (PCR or rapid antigen testing) during the admission or up to two weeks prior. The primary outcome was 90-day mortality (modified Poisson regression). Secondary outcomes were use of critical care during the admission (logistic regression) and total length-of-stay (linear regression with heteroskedastic-consistent standard-error estimators). All models were adjusted for demographic characteristics, neighbourhood socioeconomic factors and indicators of illness severity.RESULTS: There were 73,201 SARS-CoV-2-related admissions: 6127 (8%) during wave 1 (wild-type), 14,371 (20%) during wave 2 (wild-type), 16,653 (23%) during wave 3 (Alpha), 5678 (8%) during wave 4 (Delta) and 30,372 (42%) during wave 5 (Omicron). SARS-CoV-2 was the most responsible diagnosis for 70% of admissions during waves 1–2 and 42% in wave 5. The proportion of admitted patients who were long-term care residents was 18% (n = 1111) during wave 1, decreasing to 10% (n = 1468) in wave 2 and <5% in subsequent waves. During waves 1–3, 46% of all admitted patients resided in a neighbourhood assigned to the highest ethnic diversity quintile, which declined to 27% during waves 4–5. Compared to wave 1, 90-day mortality was similar during wave 2 (adjusted risk ratio [aRR]: 1.00 [95% CI: 0.95–1.04]), but lower during wave 3 (aRR: 0.89 [0.85–0.94]), wave 4 (aRR: 0.85 [0.79–0.91]) and wave 5 (aRR: 0.83 [0.80–0.88]). Improvements in survival over waves were observed among elderly patients (p-interaction <0.0001). Critical care admission was significantly less likely during wave 5 than previous waves (adjusted odds ratio: 0.50 [0.47–0.54]). The length of stay was a median of 8.5 (3.6–23.8) days during wave 1 and 5.3 (2.2–12.6) during wave 5. After adjustment, the mean length of stay was on average –10.4 (–11.1 to –9.8) days, i.e. shorter, in wave 5 vs wave 1.CONCLUSION: Throughout the pandemic, sociodemographic characteristics of patients hospitalised with SARS-CoV-2 changed over time, particularly in terms of ethnic diversity, but still disproportionately affected patients from more marginalised regions. Improved survival and reduced use of critical care during the Omicron wave are reassuring.
简介:COVID-19 大流行的每一波都表现出独特的流行病学、社会和结构特征。方法:这是一项在加拿大安大略省进行的基于人口的研究。研究纳入了 2020 年 2 月 26 日至 2022 年 3 月 31 日期间因感染 SARS-CoV-2 而住院的患者。如果省住院或门诊数据库中包含 ICD-10 诊断代码 U071/U072 或安大略省实验室信息系统显示入院期间或入院前两周内 SARS-CoV-2 检测结果(PCR 或快速抗原检测)呈阳性,则认为该患者的入院与 SARS-CoV-2 感染有关。主要结果是 90 天死亡率(修正泊松回归)。次要结果是入院期间使用重症监护(逻辑回归)和总住院时间(使用异方差一致的标准误差估计器的线性回归)。所有模型都根据人口统计学特征、社区社会经济因素和疾病严重程度指标进行了调整:第 1 波(野生型)有 6127 人(8%),第 2 波(野生型)有 14371 人(20%),第 3 波(阿尔法型)有 16653 人(23%),第 4 波(德尔塔型)有 5678 人(8%),第 5 波(奥米克隆型)有 30372 人(42%)。在第 1-2 波和第 5 波分别有 70% 和 42% 的入院患者被诊断为 SARS-CoV-2。入院患者中,长期护理居民的比例在第 1 次波次中为 18%(n = 1111),在第 2 次波次中降至 10%(n = 1468),在随后的波次中小于 5%。在第 1-3 波期间,46% 的入院患者居住在种族多样性最高的五分位数社区,而在第 4-5 波期间,这一比例下降到 27%。与第 1 波相比,第 2 波的 90 天死亡率相似(调整风险比 [aRR]:1.00 [95% CI:0.95-1.04]),但第 3 波(aRR:0.89 [0.85-0.94])、第 4 波(aRR:0.85 [0.79-0.91])和第 5 波(aRR:0.83 [0.80-0.88])较低。老年患者的存活率在各阶段均有所提高(p-交互作用<0.0001)。与前几波相比,第 5 波患者入院接受重症监护的几率明显降低(调整后的几率比:0.50 [0.47-0.54])。第 1 波的住院时间中位数为 8.5 天(3.6-23.8 天),第 5 波为 5.3 天(2.2-12.6 天)。结论:在整个大流行期间,SARS-CoV-2 住院病人的社会人口学特征随着时间的推移发生了变化,特别是在种族多样性方面,但来自较边缘化地区的病人仍然受到不成比例的影响。令人欣慰的是,在 "Omicron浪潮 "期间,患者的存活率有所提高,重症监护的使用也有所减少。
{"title":"A cohort study of patients hospitalised with SARS-CoV-2 infection in Ontario: patient characteristics and outcomes by wave","authors":"S. Habbous, Anna Lambrinos, Kirsten Ming, Erik Hellsten","doi":"10.57187/s.3636","DOIUrl":"https://doi.org/10.57187/s.3636","url":null,"abstract":"INTRODUCTION: Each wave of the COVID-19 pandemic exhibited a unique combination of epidemiological, social and structural characteristics. We explore similarities and differences in wave-over-wave characteristics of patients hospitalised with COVID-19.\u0000METHODS: This was a population-based study in Ontario province, Canada. Patients hospitalised with SARS-CoV-2 between 26 February 2020 and 31 March 2022 were included. An admission was considered related to SARS-CoV-2 infection if the provincial inpatient or outpatient hospital databases contained the ICD-10 diagnostic codes U071/U072 or the Ontario Laboratories Information System indicated a positive SARS-CoV-2 test result (PCR or rapid antigen testing) during the admission or up to two weeks prior. The primary outcome was 90-day mortality (modified Poisson regression). Secondary outcomes were use of critical care during the admission (logistic regression) and total length-of-stay (linear regression with heteroskedastic-consistent standard-error estimators). All models were adjusted for demographic characteristics, neighbourhood socioeconomic factors and indicators of illness severity.\u0000RESULTS: There were 73,201 SARS-CoV-2-related admissions: 6127 (8%) during wave 1 (wild-type), 14,371 (20%) during wave 2 (wild-type), 16,653 (23%) during wave 3 (Alpha), 5678 (8%) during wave 4 (Delta) and 30,372 (42%) during wave 5 (Omicron). SARS-CoV-2 was the most responsible diagnosis for 70% of admissions during waves 1–2 and 42% in wave 5. The proportion of admitted patients who were long-term care residents was 18% (n = 1111) during wave 1, decreasing to 10% (n = 1468) in wave 2 and <5% in subsequent waves. During waves 1–3, 46% of all admitted patients resided in a neighbourhood assigned to the highest ethnic diversity quintile, which declined to 27% during waves 4–5. Compared to wave 1, 90-day mortality was similar during wave 2 (adjusted risk ratio [aRR]: 1.00 [95% CI: 0.95–1.04]), but lower during wave 3 (aRR: 0.89 [0.85–0.94]), wave 4 (aRR: 0.85 [0.79–0.91]) and wave 5 (aRR: 0.83 [0.80–0.88]). Improvements in survival over waves were observed among elderly patients (p-interaction <0.0001). Critical care admission was significantly less likely during wave 5 than previous waves (adjusted odds ratio: 0.50 [0.47–0.54]). The length of stay was a median of 8.5 (3.6–23.8) days during wave 1 and 5.3 (2.2–12.6) during wave 5. After adjustment, the mean length of stay was on average –10.4 (–11.1 to –9.8) days, i.e. shorter, in wave 5 vs wave 1.\u0000CONCLUSION: Throughout the pandemic, sociodemographic characteristics of patients hospitalised with SARS-CoV-2 changed over time, particularly in terms of ethnic diversity, but still disproportionately affected patients from more marginalised regions. Improved survival and reduced use of critical care during the Omicron wave are reassuring.","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140245234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between the number of symptomatic mpox cases and the detection of mpox virus DNA in wastewater in Switzerland: an observational surveillance study. 瑞士无症状水痘病例数量与废水中检测到的水痘病毒 DNA 之间的关系:一项观察性监测研究。
IF 2.9 4区 医学 Q1 Medicine Pub Date : 2024-03-07 DOI: 10.57187/s.3706
Claudia Bagutti, Monica Alt Hug, Philippe Heim, Evelyn Ilg Hampe, Philipp Hübner, Timothy R Julian, Katrin N Koch, Kerstin Grosheintz, Melanie Kraus, Carla Schaubhut, Rahel Tarnutzer, Eva Würfel, Simon Fuchs, Sarah Tschudin-Sutter

Aim of the study: The COVID-19 pandemic has drawn attention to the benefit of wastewater-based epidemiology, particularly when case numbers are underreported. Underreporting may be an issue with mpox, where biological reasons and stigma may prevent patients from getting tested. Therefore, we aimed to assess the validity of wastewater surveillance for monitoring mpox virus DNA in wastewater of a Central European city and its association with official case numbers.

Methods: Wastewater samples were collected between 1 July and 28 August 2022 in the catchment area of Basel, Switzerland, and the number of mpox virus genome copies they contained was determined by real-time quantitative PCR. Logistic regression analyses were used to determine the odds of detectability of mpox virus DNA in wastewater, categorised as detectable or undetectable. Mann-Whitney U tests were used to determine associations between samples that tested positive for the mpox virus and officially reported cases and patients' recorded symptomatic phases.

Results: Mpox virus DNA was detected in 15 of 39 wastewater samples. The number of positive wastewater samples was associated with the number of symptomatic cases (odds ratio [OR] = 2.18, 95% confidence interval (CI) = 1.38-3.43, p = 0.001). The number of symptomatic cases differed significantly between days with positive versus negative wastewater results (median = 11 and 8, respectively, p = 0.0024).

Conclusion: Mpox virus DNA was detectable in wastewater, even when officially reported case numbers were low (0-3 newly reported mpox cases corresponding to 6-12 symptomatic patients). Detectability in wastewater was significantly associated with the number of symptomatic patients within the catchment area. These findings illustrate the value of wastewater-based surveillance systems when assessing the prevalence of emerging and circulating infectious diseases.

研究目的:COVID-19 大流行使人们注意到基于废水的流行病学的益处,尤其是在病例数被低报的情况下。低报可能是水痘的一个问题,因为生理原因和耻辱感可能会阻碍患者接受检测。因此,我们旨在评估废水监测对监测中欧某城市废水中天花病毒 DNA 的有效性及其与官方病例数的关联:方法:我们于 2022 年 7 月 1 日至 8 月 28 日期间在瑞士巴塞尔集水区采集了废水样本,并通过实时定量 PCR 测定了其中所含的 mpox 病毒基因组拷贝数。采用逻辑回归分析确定废水中检测到 mpox 病毒 DNA 的几率,分为可检测到和不可检测到两种情况。曼-惠特尼 U 检验用于确定水痘病毒检测呈阳性的样本与官方报告的病例和患者记录的症状阶段之间的关联:结果:39 份废水样本中有 15 份检测到麻风腮病毒 DNA。阳性废水样本的数量与有症状病例的数量相关(几率比 [OR] = 2.18,95% 置信区间 (CI) = 1.38-3.43,p = 0.001)。有症状病例的数量在废水结果为阳性和阴性的天数之间存在显著差异(中位数分别为 11 天和 8 天,p = 0.0024):结论:即使官方报告的病例数很少(0-3 个新报告的麻风病例对应 6-12 个有症状的病人),废水中也能检测到麻风病毒 DNA。废水中的可检测性与集水区内有症状患者的数量有显著关联。这些发现说明了基于废水的监测系统在评估新发和流行性传染病流行情况时的价值。
{"title":"Association between the number of symptomatic mpox cases and the detection of mpox virus DNA in wastewater in Switzerland: an observational surveillance study.","authors":"Claudia Bagutti, Monica Alt Hug, Philippe Heim, Evelyn Ilg Hampe, Philipp Hübner, Timothy R Julian, Katrin N Koch, Kerstin Grosheintz, Melanie Kraus, Carla Schaubhut, Rahel Tarnutzer, Eva Würfel, Simon Fuchs, Sarah Tschudin-Sutter","doi":"10.57187/s.3706","DOIUrl":"https://doi.org/10.57187/s.3706","url":null,"abstract":"<p><strong>Aim of the study: </strong>The COVID-19 pandemic has drawn attention to the benefit of wastewater-based epidemiology, particularly when case numbers are underreported. Underreporting may be an issue with mpox, where biological reasons and stigma may prevent patients from getting tested. Therefore, we aimed to assess the validity of wastewater surveillance for monitoring mpox virus DNA in wastewater of a Central European city and its association with official case numbers.</p><p><strong>Methods: </strong>Wastewater samples were collected between 1 July and 28 August 2022 in the catchment area of Basel, Switzerland, and the number of mpox virus genome copies they contained was determined by real-time quantitative PCR. Logistic regression analyses were used to determine the odds of detectability of mpox virus DNA in wastewater, categorised as detectable or undetectable. Mann-Whitney U tests were used to determine associations between samples that tested positive for the mpox virus and officially reported cases and patients' recorded symptomatic phases.</p><p><strong>Results: </strong>Mpox virus DNA was detected in 15 of 39 wastewater samples. The number of positive wastewater samples was associated with the number of symptomatic cases (odds ratio [OR] = 2.18, 95% confidence interval (CI) = 1.38-3.43, p = 0.001). The number of symptomatic cases differed significantly between days with positive versus negative wastewater results (median = 11 and 8, respectively, p = 0.0024).</p><p><strong>Conclusion: </strong>Mpox virus DNA was detectable in wastewater, even when officially reported case numbers were low (0-3 newly reported mpox cases corresponding to 6-12 symptomatic patients). Detectability in wastewater was significantly associated with the number of symptomatic patients within the catchment area. These findings illustrate the value of wastewater-based surveillance systems when assessing the prevalence of emerging and circulating infectious diseases.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Swiss medical weekly
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1